65,437 trials
Melanoma (Skin)
Primary: Change in Tumor Infiltration by Cluster of Differentiation 8 (CD8) Positive Cytotoxic T Lymphocytes — 289; 104; 955; 428 cells/mL
Substance Use Disorders · Methamphetamine Abuse
Primary: Methamphetamine Self-Administration — 8890; 7116 Clicks on a computer mouse
Palliative Care
Primary: Patient Health Questionnaire - 9 (PHQ-9) — 5.23; 8.83; 6.77; 7 score on a scale — p=0.09
Urinary Bladder, Neurogenic
Primary: Number of Participants With Treatment Emergent Adverse Events (AEs) and Serious Adverse Events (SAEs): Merged Data of Studies A0221047 and A0221109 — 2; 9; 2; 6…
Obesity in Children
Primary: Change in zBMI — -0.048; 0.013; 0.011 z-score — p=0.051
Pain, Postoperative
Primary: Postoperative Pain Levels — 1.3160; 2.1362 score on a scale
Angiofibromas · Tuberous Sclerosis
Primary: Change From Baseline in the Facial Angiofibroma Grading Scale (AGS) Score — -13.89; -12.71; -1.39 score on a scale
Multiple Sclerosis · Cognitive Decline
Primary: Change in Processing Speed After 6 Weeks of Treatment With a Digital Therapeutic 'Game 1', vs. 'Game 2'. — 6.10; 3.55 score on a scale
X-linked Hypophosphatemia
Primary: Safety and Efficacy of Repeated SC Injections of KRN23 — 24; 1; 1; 0 Participants
Hepatitis B
Primary: HBsAG Prevalence — 22 Participants
Gingival Tissue
Primary: Radiographic Peri-implant Bone Change (Measured in Millimeters) Between Baseline and 12 Months Follow-up. — 0.78; 0.61 millimeters
Body Fat Disorder
Primary: Percentage of Correctly Identified Pre-treatment Photos by a Panel of Blinded Independent Reviewers — 16; 15 photos
Schizophrenia
Primary: Number of Participants With Treatment-Emergent Adverse Events (Safety and Tolerability) — 289 Participants
Healthy
Primary: Change in Plasma Concentration of N-arachidonoylethanolamine — -.013; -.655 pmol/mL
Antiphospholipid Antibody Syndrome · End Stage Renal Disease
Primary: Number of Patients With Prevention of Catastrophic Antiphospholipid Antibody Syndrome (CAPS) After Kidney Transplant — 1 Participants